Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties.
The anticoagulant and antithrombotic effect of heparin has been known for many decades. Nevertheless, the knowledge of structure-activity relationships and its mechanisms of action has been rather limited. However, in recent years important progress has been made and our understanding of how heparin works has increased significantly. Based on this information, attempts have been made to modify heparin to get improved pharmacological properties. The present communication summarizes the recent development. It is shown that certain heparin derivatives of low molecular weight are highly interesting compounds from a clinical point of view. Biochemical and pharmacological properties of such a preparation named Fragmin are presented.
D001777:Blood Coagulation / Q000187:drug effects*; D004347:Drug Interactions; D005170:Factor X / Q000502:physiology; D015951:Factor Xa; D006487:Hemostasis / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008970:Molecular Weight; D009005:Monosaccharides / Q000502:physiology; D010314:Partial Thromboplastin Time; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000188:drug therapy*
D009005:Monosaccharides; D005170:Factor X; D006493:Heparin; D015951:Factor Xa